drugset / Trial / NCT00314652
Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this study is to assess the safety and efficacy of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system in subjects with osteoarthritis pain. The double-blind treatment intervention duration is 28 days.
Timeline
- Start
- 1999-06
- Primary completion
- —
- Completion
- 1999-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buprenorphine | Other / unclassified | 5 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 10 mg | Other |
| Subject | Buprenorphine | Other / unclassified | 20 mg | Other |